Skip to main content
main-content

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Timely and continuous therapy reduces conversion to progressive MS

Pietro Iaffaldano comments on real-world data showing risk factors associated with increased conversion from relapsing-remitting multiple sclerosis to secondary progressive disease (4:31).

Funding for independent interviews at ECTRIMS 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.